Potassium%2525252520chloride

# Potassium chloride ## Overview - Potassium chloride (KCl) replaces potassium and chloride in hypokalemia. - **1 mEq of potassium = 1 mmol of potassium.** - Available orally and intravenously (IV). - **IV potassium is a high-alert medication:** never administer undiluted or by IV push. Use an infusion pump and follow institutional concentration/rate limits. ## Primary Indications - Treatment or prevention of **hypokalemia**. - Potassium replacement associated with diuretic therapy, gastrointestinal losses, or inadequate intake. - IV therapy when hypokalemia is severe, symptomatic, associated with arrhythmia/ECG changes, or oral therapy is not feasible. ## Adult Dosing ### Oral replacement - **Mild-to-moderate hypokalemia:** 40–100 mEq/day PO in divided doses. - **Prevention:** commonly 20 mEq/day; adjust to laboratory results. - Give with meals and a full glass of water. - Typical maximums: - **40 mEq per dose** - **200 mEq/day** in divided doses, unless a specialist-directed/local protocol permits otherwise. - Extended-release tablets/capsules should be swallowed whole; do not crush or chew. ### IV replacement Use the least aggressive route appropriate for the patient. - **Routine replacement:** 10 mEq/hour IV. - **Severe or symptomatic hypokalemia:** 10–20 mEq/hour with continuous ECG monitoring. - Rates up to **40 mEq/hour** may be used only in critical care with central access, continuous ECG monitoring, frequent potassium checks, and a specific institutional protocol. - Common maximum concentration limits vary: - Peripheral line: often **≤40 mEq/L** - Central line: higher concentrations may be permitted by institutional protocol - Typical daily replacement is individualized; large deficits may require **100–200+ mEq/day**, divided and guided by serial potassium measurements. - **Never give IV potassium by IV push.** ## Pediatric Dosing Dosing varies by age, weight, renal function, and institutional protocol. Neonatal dosing requires a neonatal-specific protocol. ### Oral - **Treatment:** 2–4 mEq/kg/day PO divided 2–4 times daily. - Some protocols use **1–2 mEq/kg/dose**, with a usual maximum of **40 mEq/dose**. - **Prevention/maintenance:** commonly 1–2 mEq/kg/day divided doses. - Maximum daily doses vary; specialist or local pediatric protocol should guide doses above approximately **100 mEq/day**. ### IV - **Routine replacement:** 0.5–1 mEq/kg/dose IV, commonly infused over 1–2 hours. - Usual maximum: **40 mEq per dose**. - Usual maximum rate: **0.5 mEq/kg/hour**. - In life-threatening hypokalemia, up to **1 mEq/kg/hour** may be used only in an ICU with central access, continuous ECG monitoring, and an institutional protocol; do not exceed **40 mEq/hour**. - Confirm local maximum concentration and rate limits, particularly in infants and neonates. ## Dose Adjustments - **Renal impairment, oliguria, or anuria:** avoid or substantially reduce potassium; obtain specialist guidance. Do not administer routinely until urine output and renal function are established. - **Hemodialysis or severe kidney disease:** dose only with nephrology/local protocol and frequent potassium monitoring. - **Hepatic impairment:** no routine adjustment, but monitor closely if hepatorenal dysfunction is present. - Correct **hypomagnesemia**, which can make hypokalemia refractory. - Dose based on the current potassium concentration, symptoms, ECG findings, ongoing losses, and estimated deficit—not solely on a single laboratory value. ## Contraindications - Hyperkalemia. - Significant renal failure, oliguria, or anuria unless managed under specialist supervision. - Untreated adrenal insufficiency or conditions causing impaired potassium excretion. - Oral solid formulations: contraindicated in patients with significant gastrointestinal obstruction, stricture, or delayed transit. - IV administration through an infiltrated or compromised line. - Use extreme caution with significant cardiac conduction disease or concurrent potassium-raising therapy. ## Adverse Effects ### Oral - Nausea, vomiting, abdominal pain, diarrhea. - Gastrointestinal ulceration, bleeding, obstruction, or perforation—especially with solid extended-release products. - Hyperkalemia and cardiac arrhythmias. ### IV - Pain, phlebitis, and extravasation injury. - Hyperkalemia, muscle weakness, paresthesias, conduction abnormalities, ventricular arrhythmias, cardiac arrest, and death with rapid or excessive administration. - Local tissue necrosis with extravasation. ## Key Drug Interactions - **ACE inhibitors, ARBs, aliskiren:** increased hyperkalemia risk. - **Potassium-sparing diuretics** such as spironolactone, eplerenone, amiloride, and triamterene: potentially severe hyperkalemia. - **NSAIDs/COX-2 inhibitors:** reduced renal potassium excretion. - **Trimethoprim**, including trimethoprim-sulfamethoxazole: hyperkalemia risk. - **Heparin**, cyclosporine, tacrolimus, and other drugs impairing aldosterone activity: increased potassium. - **Digoxin:** hypokalemia increases digoxin toxicity; potassium replacement may reduce this risk, but excessive potassium can also cause dangerous conduction effects. - **Salt substitutes or potassium-containing supplements:** additive potassium exposure. - Drugs causing gastrointestinal irritation may increase oral KCl-related GI injury. ## Monitoring - Serum potassium before treatment and after each significant replacement dose or infusion. - Serum magnesium, sodium, bicarbonate, creatinine, BUN, and renal function. - Urine output, particularly before IV administration. - Continuous ECG monitoring for: - Severe or symptomatic hypokalemia - IV rates above routine replacement rates - Central-line infusions - Significant cardiac disease or digoxin use - Monitor for ECG changes of hypokalemia or hyperkalemia. - Inspect IV site frequently; stop infusion immediately for pain, swelling, erythema, or suspected extravasation. - Reassess ongoing gastrointestinal, renal, or medication-related potassium losses. ## Clinical Pearls - Prefer **oral potassium** when clinically appropriate; it is generally safer than IV therapy. - Do not use serum potassium alone to estimate replacement needs; total-body potassium deficit may be substantial. - Correct magnesium deficiency when potassium does not respond as expected. - IV KCl must be diluted, clearly labeled, administered via pump, and independently double-checked. - Use a central line for concentrated solutions only according to local policy. - Avoid dextrose-containing diluents when possible during urgent replacement because insulin-mediated intracellular potassium shift may transiently worsen hypokalemia. - Potassium chloride is not interchangeable in all situations with potassium phosphate or potassium acetate; select the salt based on chloride, phosphate, and acid–base status. - For oral liquid products, verify concentration carefully; formulations may differ substantially. - If potassium is used for prevention, reassess the ongoing indication and renal function regularly. > **Educational disclaimer:** This information is for educational use and does not replace clinical judgment, institutional protocols, or the current product labeling. Verify the formulation, concentration, patient-specific dose, infusion rate, and monitoring requirements in current prescribing information before use.